Cargando…

Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions

Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells in bone marrow, leading to the overproduction of monoclonal immunoglobulins. The clinical manifestations resulting from monoclonal proteins and malignant cells include signs of end-organ damage, suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chao-Chao, Li, Yi, Cheng, Zhao-Jun, Wang, Xi, Mao, Wei, Zhang, Ying-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834085/
https://www.ncbi.nlm.nih.gov/pubmed/35153791
http://dx.doi.org/10.3389/fphar.2022.818179
_version_ 1784649095436042240
author Yu, Chao-Chao
Li, Yi
Cheng, Zhao-Jun
Wang, Xi
Mao, Wei
Zhang, Ying-Wen
author_facet Yu, Chao-Chao
Li, Yi
Cheng, Zhao-Jun
Wang, Xi
Mao, Wei
Zhang, Ying-Wen
author_sort Yu, Chao-Chao
collection PubMed
description Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells in bone marrow, leading to the overproduction of monoclonal immunoglobulins. The clinical manifestations resulting from monoclonal proteins and malignant cells include signs of end-organ damage, such as hypercalcemia, renal failure, anemia, and bone lesions. Despite improvement in the survival of MM patients with use of myeloma-targeted and immunomodulatory therapies, MM remains an incurable disease. Moreover, patients with relapsed or refractory MM show poor survival outcomes. In recent years, there has been a growing interest in the use of traditional Chinese medicinal materials (TCMMs) for management of a wide spectrum of diseases. The bioactive ingredients derived from TCMMs hold great potential for the development of anticancer drugs. Here we summarize the evidence of the pharmacological effects of the active components in TCMMs on MM, including curcumin, resveratrol, baicalein, berberine, bufalin, cinobufagin, gambogic acid, ginsenoside, icariin, daidzin, formononetin, polysaccharides extracts from Hedyotis difus, and scutellarein. Available evidence indicates that the anti-MM effects of these bioactive ingredients are mediated via regulation of proliferation, apoptosis, autophagy, cell cycle, osteogenic differentiation, and drug resistance. In the future, the underlying mechanisms of the anti-MM effects of these components should be further investigated. Large-scale and well-designed clinical trials are also required to validate the efficacy of these bioactive constituents for MM.
format Online
Article
Text
id pubmed-8834085
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88340852022-02-12 Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions Yu, Chao-Chao Li, Yi Cheng, Zhao-Jun Wang, Xi Mao, Wei Zhang, Ying-Wen Front Pharmacol Pharmacology Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells in bone marrow, leading to the overproduction of monoclonal immunoglobulins. The clinical manifestations resulting from monoclonal proteins and malignant cells include signs of end-organ damage, such as hypercalcemia, renal failure, anemia, and bone lesions. Despite improvement in the survival of MM patients with use of myeloma-targeted and immunomodulatory therapies, MM remains an incurable disease. Moreover, patients with relapsed or refractory MM show poor survival outcomes. In recent years, there has been a growing interest in the use of traditional Chinese medicinal materials (TCMMs) for management of a wide spectrum of diseases. The bioactive ingredients derived from TCMMs hold great potential for the development of anticancer drugs. Here we summarize the evidence of the pharmacological effects of the active components in TCMMs on MM, including curcumin, resveratrol, baicalein, berberine, bufalin, cinobufagin, gambogic acid, ginsenoside, icariin, daidzin, formononetin, polysaccharides extracts from Hedyotis difus, and scutellarein. Available evidence indicates that the anti-MM effects of these bioactive ingredients are mediated via regulation of proliferation, apoptosis, autophagy, cell cycle, osteogenic differentiation, and drug resistance. In the future, the underlying mechanisms of the anti-MM effects of these components should be further investigated. Large-scale and well-designed clinical trials are also required to validate the efficacy of these bioactive constituents for MM. Frontiers Media S.A. 2022-01-27 /pmc/articles/PMC8834085/ /pubmed/35153791 http://dx.doi.org/10.3389/fphar.2022.818179 Text en Copyright © 2022 Yu, Li, Cheng, Wang, Mao and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yu, Chao-Chao
Li, Yi
Cheng, Zhao-Jun
Wang, Xi
Mao, Wei
Zhang, Ying-Wen
Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
title Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
title_full Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
title_fullStr Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
title_full_unstemmed Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
title_short Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
title_sort active components of traditional chinese medicinal material for multiple myeloma: current evidence and future directions
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834085/
https://www.ncbi.nlm.nih.gov/pubmed/35153791
http://dx.doi.org/10.3389/fphar.2022.818179
work_keys_str_mv AT yuchaochao activecomponentsoftraditionalchinesemedicinalmaterialformultiplemyelomacurrentevidenceandfuturedirections
AT liyi activecomponentsoftraditionalchinesemedicinalmaterialformultiplemyelomacurrentevidenceandfuturedirections
AT chengzhaojun activecomponentsoftraditionalchinesemedicinalmaterialformultiplemyelomacurrentevidenceandfuturedirections
AT wangxi activecomponentsoftraditionalchinesemedicinalmaterialformultiplemyelomacurrentevidenceandfuturedirections
AT maowei activecomponentsoftraditionalchinesemedicinalmaterialformultiplemyelomacurrentevidenceandfuturedirections
AT zhangyingwen activecomponentsoftraditionalchinesemedicinalmaterialformultiplemyelomacurrentevidenceandfuturedirections